Synageva BioPharma Corp.
(NASDAQ : GEVA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.55%304.021.4%$590.01m
AMGNAmgen, Inc.
0.48%234.531.3%$520.40m
GILDGilead Sciences, Inc.
2.32%67.461.0%$372.04m
REGNRegeneron Pharmaceuticals, Inc.
1.23%372.872.6%$304.18m
VRTXVertex Pharmaceuticals, Inc.
0.25%223.631.9%$268.79m
ILMNIllumina, Inc.
2.12%326.583.5%$238.02m
ARWRArrowhead Pharmaceuticals, Inc.
1.88%66.7612.0%$190.73m
EXASEXACT Sciences Corp.
3.62%86.6424.0%$184.91m
ALXNAlexion Pharmaceuticals, Inc.
6.24%114.122.0%$180.74m
CLVSClovis Oncology, Inc.
9.24%9.6814.7%$177.12m
SRPTSarepta Therapeutics, Inc.
-0.58%109.3214.6%$147.96m
AAgilent Technologies, Inc.
0.87%82.241.6%$141.71m
BMRNBioMarin Pharmaceutical, Inc.
0.61%80.574.3%$130.89m
SGENSeattle Genetics, Inc.
0.29%117.506.1%$128.26m
NBIXNeurocrine Biosciences, Inc.
-0.23%116.215.0%$127.26m

Company Profile

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded on November 2, 2011 and is headquartered in Lexington, MA.